Experimental drug Zmapp, produced and manufactured by Mapp Biopharmaceutical Inc, has been recently sent to Liberia to treat doctors affected by Ebola virus.
A result of the drug administration has not been posted.
The World Health Organization (WHO), alarmed by the outbreak of Ebola virus, approved the administration of an experimental drug to the doctors affected by the virus while treating Liberian patients.
The WHO said that this is "the world's worst outbreak" of Ebola in history. Up until this point, the WHO stated that there have been 1,069 victims and 1,975 apparent and alleged cases in across four West African countries, reported Reuters.
The downfall of the drug is that "cure to the catastrophic virus Zmapp", is that the drug has never been tested. As Tolbert Nyenswah, an assistant health minister of Liberia validated "This is not the panacea, solution, to the problem. It is at the risk of the patient."
Marie Paule Kieny, WHO assistant director-general, stated that they find themselves in a sticky situation in approving the experimental drug.
The WHO added that they have resorted to this drug, regardless the stir that the ZMapp has caused, for the key reason that "too many lives are taken" by the virus, according to The Wall Street Journal.
Hence comes the question: "Who can recieve the drug?" since only less than 13 doses of the drug have been manufactured thus far, stated The U.N. health organization.
